セルメチニブ

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Danger

• 危険有害性情報

  H317：アレルギー性皮膚反応を起こすおそれ

  H318：重篤な眼の損傷

  H373：長期にわたる、または反復暴露により臓器の障 害のおそれ

• 注意書き

  P262：眼、皮膚、衣類につけないこと。

  P280：保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。

  P312：気分が悪い時は医師に連絡すること。

セルメチニブ 価格

セルメチニブ 化学特性,用途語,生産方法

• 効能

  抗悪性腫瘍薬, マイトジェン活性化細胞外シグナル関連キナーゼ(MEK)阻害薬

• 説明

  Selumetinib (AZD6244; ARRY-142886) is an oral MEK inhibitor. In a randomized trial, NSCLC patients with wild-type KRAS were randomized to erlotinib alone or combination therapy with selumetinib, while mutant KRAS patients were randomized to selumetinib alone or combination therapy. The primary end points were PFS for the KRAS wild-type cohort and objective response rate (ORR) for the KRAS mutant cohort. Results were not impressive, with no PFS difference in the KRAS wild-type arm (2.4 vs. 2.1?months) and no ORR difference in the KRASmutated subgroup (0% vs. 10%). A planned trial of selumetinib in combination with the anti-PD-L1 antibody durvalumab has since been suspended (NCT03004105).

• 定義

  ChEBI: A member of the class of benzimidazoles that is 1-methyl-1H-benzimidazole which is substituted at positions 4, 5, and 6 by fluorine, (4-bromo-2-chlorophenyl)amino, and N-(2-hydroxyethoxy)aminocarbonyl groups, respectiv ly. It is a MEK1 and MEK2 inhibitor.

• brand name

  Koselugo

• 一般的な説明

  Class: dual threonine/tyrosine kinase; Treatment: children with NF1; Other name: AZD-6244, ARRY-142886; Oral bioavailability = 62%; Elimination half-life = 6.2 h; Protein binding = 97.7%

• Dosage

  Selumetinib is characterized by a moderate oral bioavailability (62%) and a relatively short half-life (6.2 h), and these properties contribute to twice-daily dosing regimen (25 mg dosage).

セルメチニブ 上流と下流の製品情報

セルメチニブ 生産企業

Global(328)Suppliers

セルメチニブ スペクトルデータ(¹HNMR)

606143-52-6, セルメチニブ キーワード